CN114206883A - 氧代吡啶稠环衍生物及包含该衍生物的药物组合物 - Google Patents

氧代吡啶稠环衍生物及包含该衍生物的药物组合物 Download PDF

Info

Publication number
CN114206883A
CN114206883A CN202080056144.2A CN202080056144A CN114206883A CN 114206883 A CN114206883 A CN 114206883A CN 202080056144 A CN202080056144 A CN 202080056144A CN 114206883 A CN114206883 A CN 114206883A
Authority
CN
China
Prior art keywords
fluorophenyl
oxo
pyridine
carboxamide
oxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080056144.2A
Other languages
English (en)
Chinese (zh)
Inventor
柳贤
李政垠
高永玉
金用锡
朴慧彬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Weimaike Biology Co ltd
Original Assignee
Weimaike Biology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Weimaike Biology Co ltd filed Critical Weimaike Biology Co ltd
Publication of CN114206883A publication Critical patent/CN114206883A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202080056144.2A 2019-08-02 2020-08-03 氧代吡啶稠环衍生物及包含该衍生物的药物组合物 Pending CN114206883A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20190094455 2019-08-02
KR10-2019-0094455 2019-08-02
PCT/KR2020/010204 WO2021025407A1 (ko) 2019-08-02 2020-08-03 옥소-피리딘 융합고리 유도체 및 이를 포함하는 약학적 조성물

Publications (1)

Publication Number Publication Date
CN114206883A true CN114206883A (zh) 2022-03-18

Family

ID=74503219

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080056144.2A Pending CN114206883A (zh) 2019-08-02 2020-08-03 氧代吡啶稠环衍生物及包含该衍生物的药物组合物

Country Status (6)

Country Link
US (1) US20220235064A1 (https=)
EP (1) EP4011885A4 (https=)
JP (1) JP2022543250A (https=)
KR (1) KR20210015730A (https=)
CN (1) CN114206883A (https=)
WO (1) WO2021025407A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115003307A (zh) * 2020-02-06 2022-09-02 伟迈可生物有限公司 用于预防或治疗与kras突变相关的癌症的药物组合物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210111711A (ko) * 2020-03-03 2021-09-13 웰마커바이오 주식회사 Kras 돌연변이 및 활성화된 ron이 존재하는 암의 예방 또는 치료용 약학 조성물
JP2023526443A (ja) * 2020-05-18 2023-06-21 ウェルマーカー バイオ カンパニー リミテッド Ｒｏｎ変異が関与する非小細胞肺がんの予防又は治療用医薬組成物及びその使用方法
US20230202992A1 (en) * 2020-05-18 2023-06-29 Wellmarker Bio Co., Ltd. Pharmaceutical composition for preventing or treating small-cell lung cancer associated with ron mutants and method using same
KR20210142555A (ko) * 2020-05-18 2021-11-25 웰마커바이오 주식회사 Ron 돌연변이와 관련된 췌장암 예방 또는 치료용 약학 조성물 및 이를 이용한 방법
KR20220152155A (ko) * 2021-05-07 2022-11-15 웰마커바이오 주식회사 Ron 돌연변이와 관련된 담도암 예방 또는 치료용 약학 조성물
KR20220170766A (ko) * 2021-06-22 2022-12-30 주식회사 엘지화학 단백질 키나아제 억제제로서의 신규한 화합물

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070197537A1 (en) * 2006-01-30 2007-08-23 Blake James F Heterobicyclic thiophene compounds and methods of use
US20140088114A1 (en) * 2011-05-16 2014-03-27 OSI Pharmaceuticals ,LLC Fused bicyclic kinase inhibitors
US20140206679A1 (en) * 2011-06-09 2014-07-24 Shanghai Huilun Life Science & Technology Co., Ltd Heterocyclic pyridone compound, and intermediate, preparation method and use thereof
CN103965107A (zh) * 2013-02-06 2014-08-06 沈阳药科大学 2-芳基取代喹啉类化合物及其用途
US20140228379A1 (en) * 2011-08-10 2014-08-14 Merck Patent Gmbh Pyrido-Pyrimidine Derivatives
US20150299219A1 (en) * 2014-04-22 2015-10-22 Calitor Sciences, Llc Bicyclic pyrazolone compounds and methods of use
US20170349583A1 (en) * 2014-12-25 2017-12-07 Ono Pharmaceutical Co., Ltd. Quinoline derivative
CN108314682A (zh) * 2018-01-31 2018-07-24 江西科技师范大学 6,7-双取代-4-芳杂喹啉类化合物的制备及应用
CN109096250A (zh) * 2018-09-25 2018-12-28 辽宁大学 含哒嗪酮的4-苯氧基吡啶类化合物及其应用
CN111295386A (zh) * 2018-03-08 2020-06-16 伟迈可生物有限公司 噻吩并吡啶衍生物及含有该衍生物的药物组合物
CN115209900A (zh) * 2020-03-03 2022-10-18 伟迈可生物有限公司 用于预防或治疗其中存在kras突变和活化ron的癌症的药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539878A (ja) * 2006-06-08 2009-11-19 アレイ バイオファーマ、インコーポレイテッド キノリン化合物および使用方法
SI2089364T1 (sl) * 2006-11-08 2013-10-30 Bristol-Myers Squibb Company Spojine piridinona
EP2423208A1 (en) * 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
DK2820009T3 (en) 2012-03-01 2018-04-16 Array Biopharma Inc Serine / threonine kinase inhibitors
WO2014038881A2 (ko) * 2012-09-06 2014-03-13 씨제이제일제당 (주) 피리돈 유도체를 포함하는 단백질 키나제 억제제
US11946934B2 (en) * 2014-09-03 2024-04-02 Wellmarker Bio Co., Ltd. Biomarker for predicting the sensitivity to a protein kinase inhibitor and a use thereof
US11623923B2 (en) * 2017-11-24 2023-04-11 Medshine Discovery, Inc. Uracil compound as c-MET/AXL inhibitor

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070197537A1 (en) * 2006-01-30 2007-08-23 Blake James F Heterobicyclic thiophene compounds and methods of use
US20140088114A1 (en) * 2011-05-16 2014-03-27 OSI Pharmaceuticals ,LLC Fused bicyclic kinase inhibitors
US20140206679A1 (en) * 2011-06-09 2014-07-24 Shanghai Huilun Life Science & Technology Co., Ltd Heterocyclic pyridone compound, and intermediate, preparation method and use thereof
US20140228379A1 (en) * 2011-08-10 2014-08-14 Merck Patent Gmbh Pyrido-Pyrimidine Derivatives
CN103965107A (zh) * 2013-02-06 2014-08-06 沈阳药科大学 2-芳基取代喹啉类化合物及其用途
US20150299219A1 (en) * 2014-04-22 2015-10-22 Calitor Sciences, Llc Bicyclic pyrazolone compounds and methods of use
US20170349583A1 (en) * 2014-12-25 2017-12-07 Ono Pharmaceutical Co., Ltd. Quinoline derivative
CN108314682A (zh) * 2018-01-31 2018-07-24 江西科技师范大学 6,7-双取代-4-芳杂喹啉类化合物的制备及应用
CN111295386A (zh) * 2018-03-08 2020-06-16 伟迈可生物有限公司 噻吩并吡啶衍生物及含有该衍生物的药物组合物
CN109096250A (zh) * 2018-09-25 2018-12-28 辽宁大学 含哒嗪酮的4-苯氧基吡啶类化合物及其应用
CN115209900A (zh) * 2020-03-03 2022-10-18 伟迈可生物有限公司 用于预防或治疗其中存在kras突变和活化ron的癌症的药物组合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115003307A (zh) * 2020-02-06 2022-09-02 伟迈可生物有限公司 用于预防或治疗与kras突变相关的癌症的药物组合物

Also Published As

Publication number Publication date
JP2022543250A (ja) 2022-10-11
US20220235064A1 (en) 2022-07-28
WO2021025407A1 (ko) 2021-02-11
EP4011885A4 (en) 2023-01-18
KR20210015730A (ko) 2021-02-10
EP4011885A1 (en) 2022-06-15

Similar Documents

Publication Publication Date Title
CN114206883A (zh) 氧代吡啶稠环衍生物及包含该衍生物的药物组合物
AU2009217982B2 (en) Fused heterocyclic derivative and use thereof
CN102399233B (zh) PI3K和mTOR双重抑制剂类化合物
WO2024006445A1 (en) Methods for treatment of cancer
IL311024A (en) Substituted tricyclic compounds as parp inhibitors and use thereof
JP2022526854A (ja) ホスファチジルイノシトール３－キナーゼ阻害剤
WO2005105814A1 (en) Tetracyclic inhibitors of janus kinases
CN105732637B (zh) 杂芳化合物及其在药物中的应用
JP7247092B2 (ja) キナーゼ阻害剤としての置換された縮合ヘテロアリール化合物及びその用途
JP6109880B2 (ja) 三環式アザインドール
WO2021003314A1 (en) Heterocyclic compounds as kinase inhibitors
TW202039484A (zh) 雜環化合物
EP4165045A1 (en) Dual kinase-bromodomain inhibitors
WO2022037630A1 (zh) 四环类衍生物、其制备方法及其医药上的用途
US20230348462A1 (en) Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
WO2009001021A1 (en) Imidazopyridine derivatives useful as enzyme inhibitors for the treatment of cell proliferative and autoimmune diseases
AU2014384476B2 (en) Indoloquinolone compounds as anaplastic lymphoma kinase (ALK) inhibitors
ES2962136T3 (es) Compuestos de pirimidina fusionados como moduladores de KCC2
JP7763538B2 (ja) Ｐａｒｐ７阻害剤及びその使用
JP6378138B2 (ja) Ｃ環修飾型三環式ベンゾナフチリジノン・タンパク質キナーゼ阻害薬及びこれらの使用
CN115667251A (zh) 杂芳基衍生物化合物、及其用途
CN120441596A (zh) 嘧啶并杂环类化合物、其药物组合物及其用途
TWI894448B (zh) Ctla-4小分子降解劑及其應用
CN118525018A (zh) 一种联炔类化合物及其应用
HK40002986A (zh) 吡啶并嘧啶酮cdk2/4/6抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
AD01 Patent right deemed abandoned

Effective date of abandoning: 20250822